Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors

Trial Profile

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Jan 2019

At a glance

  • Drugs Lifileucel (Primary) ; LN 145 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Head and neck cancer; Large cell carcinoma; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 02 Jan 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2018 to 1 Jan 2019.
    • 06 Nov 2018 According to an Iovance Biotherapeutics media release, there are currently two sites active for this trial.
    • 18 Oct 2018 According to an Iovance Biotherapeutics media release, he company is planning to start this trial in Europe and have received approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top